Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Evaluating the Immunogenicity and Safety of Ad26.COV2.S Vaccine in Adult Participants in Mali

NCT05409261 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT05409261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05409261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Evaluating the Immunogenicity and Safety of Ad26.COV2.S Vaccine in Adult Participants in Mali
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Phase 2
Overall status
Unknown status
Start date
June 2, 2022
Completion date
March 31, 2025
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars cov 2 infection, vaccine adverse reaction, vaccine reaction